DAWN
Day One Biopharmaceuticals, Inc. NASDAQ$21.53
Mkt Cap $2.2B
52w Low $5.63
100.0% of range
52w High $21.53
50d MA $18.21
200d MA $10.72
P/E (TTM)
-20.7x
EV/EBITDA
-7.3x
P/B
5.0x
Debt/Equity
0.0x
ROE
-24.3%
P/FCF
-9.3x
RSI (14)
—
ATR (14)
—
Beta
-1.75
50d MA
$18.21
200d MA
$10.72
Avg Volume
4.0M
About
Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/progressive low-grade glioma. Th…
Recent Earnings
| Date | Time | Est | Rptd | Surp | Base | Gap% | D1% | D2% | D3% | D4% | D5% | Guide ▲★ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 24, 2026 | AMC | -0.17 | -0.20 | -17.6% | 12.02 | -9.3% | -9.1% | -11.4% | -11.8% | -13.7% | -16.6% | — |
| Nov 4, 2025 | AMC | -0.28 | -0.19 | +31.8% | 7.30 | +8.4% | +25.2% | +23.2% | +33.3% | +39.2% | +41.9% | — |
| Aug 5, 2025 | AMC | -0.35 | -0.29 | +17.1% | 6.88 | -13.5% | -15.7% | -12.4% | -11.3% | -14.2% | -10.8% | — |
| May 6, 2025 | AMC | -0.46 | -0.35 | +23.9% | 6.99 | +7.6% | -9.9% | -3.3% | -7.7% | -5.9% | -9.4% | — |
| Feb 25, 2025 | AMC | -0.35 | -0.69 | -97.1% | 11.82 | -11.9% | -16.5% | -20.1% | -23.4% | -30.2% | -27.2% | — |
| Oct 30, 2024 | AMC | -0.41 | 0.38 | +192.7% | 14.47 | +10.1% | +1.7% | +1.2% | +2.3% | +4.7% | +6.6% | — |
| Jul 30, 2024 | AMC | -0.67 | -0.05 | +92.5% | 15.19 | +0.5% | -5.8% | -6.7% | -8.4% | -12.7% | -13.7% | — |
| May 6, 2024 | AMC | -0.67 | -0.72 | -7.5% | 16.60 | +1.2% | +2.9% | -1.1% | -1.3% | -3.6% | -3.3% | — |
| Feb 26, 2024 | AMC | -0.57 | -0.64 | -12.3% | 15.65 | +0.8% | +11.1% | +7.5% | +6.9% | +11.6% | +7.9% | — |
| Nov 6, 2023 | AMC | -0.60 | -0.54 | +10.0% | 12.19 | +0.7% | +1.4% | -0.4% | -8.0% | -6.9% | -6.6% | — |
Recent Analyst Ratings
| Date | Firm | Action | Grade | Target | Base | Open | Gap% | D1% | D2% | D3% | D4% | D5% |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mar 11 | JP Morgan | Downgrade | Overweight → Neutral | — | $21.28 | $21.27 | -0.0% | -0.1% | -0.0% | +0.1% | +0.4% | +0.0% |
| Mar 10 | HC Wainwright & Co. | Downgrade | Buy → Neutral | — | $21.33 | $21.28 | -0.2% | -0.2% | -0.4% | -0.3% | -0.1% | +0.1% |
| Mar 9 | Wedbush | Downgrade | Outperform → Neutral | — | $21.20 | $21.19 | -0.0% | +0.6% | +0.4% | +0.2% | +0.3% | +0.5% |
| Mar 6 | Needham | Downgrade | Buy → Hold | — | $12.78 | $21.13 | +65.3% | +65.9% | +66.9% | +66.5% | +66.3% | +66.4% |
| Mar 6 | Jones Trading | Downgrade | Buy → Hold | — | $12.78 | $21.13 | +65.3% | +65.9% | +66.9% | +66.5% | +66.3% | +66.4% |
| Feb 25 | Needham | Maintains | Buy → Buy | — | $12.02 | $10.90 | -9.3% | -9.1% | -11.4% | -11.8% | -13.7% | -16.6% |
| Feb 25 | Wedbush | Maintains | Outperform → Outperform | — | $12.02 | $10.90 | -9.3% | -9.1% | -11.4% | -11.8% | -13.7% | -16.6% |
| Feb 25 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $12.02 | $10.90 | -9.3% | -9.1% | -11.4% | -11.8% | -13.7% | -16.6% |
| Nov 24 | Needham | Maintains | Buy → Buy | — | $8.52 | $8.51 | -0.1% | +4.2% | +10.7% | +10.4% | +11.4% | +3.1% |
| Nov 24 | HC Wainwright & Co. | Maintains | Buy → Buy | — | $8.52 | $8.51 | -0.1% | +4.2% | +10.7% | +10.4% | +11.4% | +3.1% |
Recent Filings
8-K
Aura Biosciences, Inc. -- 8-K Filing
Aura Biosciences appointed an experienced pharmaceutical executive as Chief Operating Officer who previously led corporate development at Hyperion Therapeutics before its acquisition by Horizon Pharma.
May 4
SC TO-T
!!! Very High
Day One Biopharmaceuticals, Inc. -- Tender Offer
Ajinkyotsu Pharma's tender offer for Day One Biopharmaceuticals (DAWN) will provide shareholders a liquidity event at a predetermined price, though deal terms and valuation details require further disclosure review.
Apr 23
8-K · 5.02
!!! Very High
Day One Biopharmaceuticals, Inc. -- 8-K 5.02: Executive Change
Day One Biopharmaceuticals' tender offer expired with 85.34% of shares validly tendered, indicating substantial shareholder acceptance of the acquisition or recapitalization proposal.
Apr 23
SC TO-T
!!! Very High
Unknown — Tender Offer
DAWN shareholders have an opportunity to sell shares at a predetermined price in a tender offer, which could provide liquidity but may signal the company faces acquisition or financial challenges requiring external validation.
Apr 14
SC TO-T
!!! Very High
Unknown — Tender Offer
DAWN shareholders face a potential change of control through this tender offer, making immediate evaluation of the offer price versus intrinsic value critical for deciding whether to accept or reject.
Apr 8
SC TO-T
!!! Very High
Unknown — Tender Offer
DAWN shareholders can sell shares at a premium price through this tender offer, providing liquidity but potentially signaling an acquisition or significant corporate restructuring ahead.
Mar 26
SC TO-T
!!! Very High
Unknown — Tender Offer
DAWN shareholders have an opportunity to sell shares at a predetermined price through a tender offer, suggesting potential acquisition or restructuring that could provide liquidity or signal management's view of undervaluation.
Mar 26
8-K
Day One Biopharmaceuticals, Inc. -- 8-K Filing
Day One Biopharmaceuticals (DAWN) has completed an acquisition and filed audited financial statements for the acquired target company, signaling deal closure and integration commencement.
Mar 9
8-K
Day One Biopharmaceuticals, Inc. -- 8-K Filing
Day One Biopharmaceuticals is proceeding with a merger transaction where closing conditions have been substantially satisfied, with no material adverse effects identified affecting the deal's completion.
Mar 6
8-K · 7.01
! Medium
Day One Biopharmaceuticals, Inc. -- 8-K 7.01: Regulation FD Disclosure
Day One Biopharmaceuticals secured a significant revenue opportunity by granting Ipsen exclusive commercialization rights to OJEMDA outside the U.S., expanding the drug's market reach internationally.
Mar 2
Data updated apr 25, 2026 4:39am
· Source: massive.com